MaxCyte Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

MaxCyteDer Gewinn des Unternehmens wird voraussichtlich um 1.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 19.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 1.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -18.8% betragen.

Wichtige Informationen

-1.9%

Wachstumsrate der Gewinne

-1.2%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	22.5%
Wachstumsrate der Einnahmen	19.3%
Zukünftige Eigenkapitalrendite	-18.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	01 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Recent updates

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

May 30

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

May 10

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Mar 14

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

May 15

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

May 14

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Apr 27

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Nov 20

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Mar 02

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Nov 17

We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn

Jul 25

MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain

Feb 22

If You Had Bought MaxCyte (LON:MXCT) Shares A Year Ago You'd Have Earned 249% Returns

Nov 24

Gewinn- und Umsatzwachstumsprognosen

AIM:MXCT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	65	-34	-47	-27	3
12/31/2025	47	-45	-58	-33	8
12/31/2024	36	-49	-59	-40	8
3/31/2024	44	-37	-31	-28	N/A
12/31/2023	41	-38	-25	-22	N/A
9/30/2023	38	-37	-34	-29	N/A
6/30/2023	41	-33	-34	-26	N/A
3/31/2023	41	-30	-29	-15	N/A
12/31/2022	44	-24	-33	-15	N/A
9/30/2022	42	-24	-27	-10	N/A
6/30/2022	41	-20	-20	-4	N/A
3/31/2022	39	-16	-19	-10	N/A
12/31/2021	34	-19	-15	-11	N/A
9/30/2021	32	-17	-15	-12	N/A
6/30/2021	29	-17	-14	-12	N/A
3/31/2021	27	-16	-10	-8	N/A
12/31/2020	26	-12	-11	-9	N/A
9/30/2020	24	-11	-10	-8	N/A
6/30/2020	24	-9	-10	-8	N/A
3/31/2020	23	-11	-13	-11	N/A
12/31/2019	22	-13	-10	-9	N/A
9/30/2019	20	-13	-11	-10	N/A
6/30/2019	18	-14	-11	-10	N/A
3/31/2019	17	-11	-11	-10	N/A
12/31/2018	17	-9	-11	-10	N/A
9/30/2018	16	-10	-11	-11	N/A
6/30/2018	15	-10	-12	-11	N/A
3/31/2018	14	-10	-11	-10	N/A
12/31/2017	14	-10	N/A	-10	N/A
9/30/2017	13	-8	N/A	-8	N/A
6/30/2017	13	-6	N/A	-6	N/A
3/31/2017	13	-5	N/A	-4	N/A
12/31/2016	12	-4	N/A	-2	N/A
9/30/2016	11	-4	N/A	-2	N/A
6/30/2016	11	-3	N/A	-2	N/A
3/31/2016	10	-3	N/A	-1	N/A
12/31/2015	9	-4	N/A	0	N/A
9/30/2015	9	-4	N/A	0	N/A
6/30/2015	8	-4	N/A	0	N/A
3/31/2015	8	-4	N/A	-1	N/A
12/31/2014	7	-4	N/A	-2	N/A
12/31/2013	7	-3	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MXCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MXCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MXCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MXCTDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: MXCTDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MXCT wird voraussichtlich in 3 Jahren unrentabel sein.

MaxCyte Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Recent updates

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index

Insider notifies of intention to sell stock

President recently bought UK£384k worth of stock

Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%

Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates fall by 13%

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

Founder exercised options and sold UK£100k worth of stock

Independent Non-Executive Director notifies of intention to sell stock

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%

Consensus revenue estimates fall by 22%

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

Founder exercised options and sold UK£173k worth of stock

Consensus revenue estimates fall by 11%

MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%

Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

High number of new directors

Key Executive recently bought UK£280k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

Founder exercised options and sold UK£139k worth of stock

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Founder exercised options and sold UK£127k worth of stock

Insider exercised options and sold UK£113k worth of stock

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth

Consensus forecasts updated

MaxCyte, Inc. Provides Revenue Guidance for 2022

Insider exercised options and sold UK£154k worth of stock

Insider exercised options and sold UK£147k worth of stock

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022